4/A//SEC Filing
Sprague John M 4/A
Accession 0000899243-22-012641
CIK 0001492674other
Filed
Mar 28, 8:00 PM ET
Accepted
Mar 29, 4:17 PM ET
Size
11.6 KB
Accession
0000899243-22-012641
Insider Transaction Report
Form 4/AAmended
Transactions
- Exercise/Conversion
Common Stock
2022-02-21+10,000→ 55,414 total - Award
Restricted Stock Units
2022-02-20+600,000→ 600,000 total→ Common Stock (600,000 underlying) - Tax Payment
Common Stock
2022-02-21$0.47/sh−3,775$1,759→ 51,639 total - Exercise/Conversion
Restricted Stock Units
2022-02-21−10,000→ 0 total→ Common Stock (10,000 underlying)
Footnotes (6)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Includes 3,968 shares acquired under the Issuer's employee stock purchase plan ("ESPP") on May 15, 2021 and 5,961 shares acquired under the ESPP on November 15, 2021.
- [F3]3,775 shares of common stock were automatically withheld at vesting to cover required tax withholding.
- [F4]The Form 4, as originally filed, incorrectly reported the amount of beneficially owned securities as 138,775.
- [F5]On February 20, 2022 the reporting person was granted 600,000 RSU's that vest in three equal installments commencing on February 20, 2023.
- [F6]On February 21, 2019 the reporting person was granted 30,000 RSU's that vest in three equal annual installments beginning on February 21, 2020.
Documents
Issuer
T2 Biosystems, Inc.
CIK 0001492674
Entity typeother
Related Parties
1- filerCIK 0001730056
Filing Metadata
- Form type
- 4/A
- Filed
- Mar 28, 8:00 PM ET
- Accepted
- Mar 29, 4:17 PM ET
- Size
- 11.6 KB